Benchmark analyst Robert Wasserman downgrades Emergent BioSolutions (NYSE:EBS) from Buy to Hold.
Benchmark Downgrades Emergent BioSolutions to Hold
Benchmark analyst Robert Wasserman downgrades Emergent BioSolutions (NYSE:EBS) from Buy to Hold.
Related Posts
‘Google Announcing Humboldt, The First Cable Route Between South America And Asia-Pacific’
https://cloud.google.com/blog/products/infrastructure/announcing-humboldt-the-first-cable-route-between-south-america-and-asia-pacific/Today, we're joining Desarrollo País of Chile and Office of Posts and
Telsey Advisory Group Maintains Outperform on a.k.a. Brands Holding, Lowers Price Target to $6
Telsey Advisory Group analyst Dana Telsey maintains a.k.a. Brands Holding (NYSE:AKA) with a Outperform and lowers the price target from $9 to $6.
Apple Announced COVID-19 Restrictions have Temporarily impacted the Primary iPhone® 14 Pro and iPhone 14 Pro Max Assembly Facility in Zhengzhou, China
COVID-19 restrictions have temporarily impacted the primary iPhone® 14 Pro and iPhone 14 Pro Max assembly facility located in Zhengzhou, China. The facility is currently operating at significantly reduced capacity. As we have done throughout the COVID-19 pandemic, we are prioritizing the health and safety of the workers in our supply chain.